New drug targets Hard-to-Treat cancers in people with BRCA2 or PALB2 mutations
Disease control
Recruiting now
This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…
Phase: PHASE1 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC